Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active crohn’s disease: Results from the VISIBLE 2 randomised trial
J Crohns Colitis. 2022 Jan 28;16(1):27-38 doi: 10.1093/ecco-jcc/jjab133
The authors highlighted a significantly greater clinical remission rate at Week 52 for vedolizumab SC versus placebo in patients with moderately to severely active CD. This study aimed to report results from VISIBLE 2 which evaluated a new SC vedolizumab formulation as maintenance treatment in adults with moderately to severely active CD.
Higher rates of CDAI-based PRO2 and PRO3 clinical remission were observed with vedolizumab SC maintenance treatment compared with placebo, suggesting that vedolizumab SC may enhance relief of patient-perceived symptoms. The safety of vedolizumab SC was also consistent with the known safety profile of vedolizumab IV therapy in patients with CD.
